IN8bio (INAB) AI Stock Analysis

• Market Cap: $10.21M
• Dividend Yield: N/A
• Average Volume (3M): 132.10K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.58
• Revenue Growth: N/A
• EPS Growth: 58.67%
• Country: US
• Employees: 18
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -1.24
• Shares Outstanding: 4,539,717
• 10 Day Avg. Volume: 106,662
• 30 Day Avg. Volume: 132,101
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.15
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 2.38
• Enterprise Value/Ebitda: 0.06
• 1Y Price Target: $3.00
• Price Target Upside: 33.33% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 34 Underperform
• Price Target: ―

IN8bio's stock score reflects significant financial challenges, typical of early-stage biotechnology companies. The financial performance is hindered by substantial operational losses and reliance on external funding, while technical analysis shows bearish market trends. Valuation remains speculative with a negative P/E ratio, emphasizing the high-risk nature of investing in developmental biotech firms.

Positive Factors

Clinical Trial Success

Multiple doses of INB-200 showed mPFS of 16.1 months, beating historical benchmarks of 6.2 months and 10.3 months in GBM patients with unmethylated or methylated MGMT promoter, respectively.

Preclinical Data

IN8bio presented promising preclinical data with their CD19 targeting γδ TCE (INB-619) showing deep B cell depletion in lupus patient blood samples.

Safety Profile

No new safety concerns were reported. No DLT, ICANS, CRS, or DRI-.

Negative Factors

Clinical Trial Suspension

IN8bio suspended enrollment in their clinical trials evaluating INB-200 and '400 in GBM last year, and is actively exploring strategic partnerships and other potential opportunities to further develop this program.

Response Variability

Some antibodies remained in the samples, particularly from Donor 3, where B cell depletion was observed after 6 days, indicating variability in response time.

IN8bio Business Overview & Revenue Model

Company Description

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

How the Company Makes Money

IN8bio generates revenue primarily through collaborations and strategic partnerships with other biotechnology and pharmaceutical companies. These partnerships involve licensing agreements, milestone payments, and royalties linked to the development and commercialization of its proprietary gamma-delta T cell therapies. Additionally, the company may receive funding from grants and research support from governmental agencies or non-profit organizations interested in advancing cancer immunotherapy research. As IN8bio progresses towards commercialization, revenue streams may also include direct sales of approved therapies, pending successful clinical trials and regulatory approvals.

IN8bio Financial Statement Overview

Summary

IN8bio's financial performance reflects a typical biotechnology company in the developmental stage, with a strong reliance on external funding due to non-existent revenues and substantial operational losses. While the company has managed to secure financing to support operations, the declining equity and significant negative cash flows present financial stability challenges in the long term.

Income Statement

IN8bio has consistently reported zero revenue over the years, which is typical for early-stage biotechnology firms that rely on funding rather than sales. The company has reported increasing net losses annually, with a net income of -$30.4 million in the most recent year, reflecting significant operational expenses and R&D costs.

Balance Sheet

The company's balance sheet shows a declining stockholders' equity from $38.2 million in 2021 to $14.5 million in 2024, indicating substantial use of equity to fund operations. The debt-to-equity ratio has increased, reflecting increased reliance on debt despite a relatively low total debt level. The equity ratio has also decreased, indicating a higher proportion of liabilities in the capital structure.

Cash Flow

IN8bio's cash flow statements reveal large negative free cash flows, primarily due to substantial operating cash outflows. The company has been relying heavily on financing activities to fund its operations, as seen in significant financing cash inflows. This pattern highlights potential liquidity risks if external financing becomes unavailable.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-631.00K	-2.65M	-2.50M	-1.10M	-251.00K	-96.00K
EBITDA	-24.36M	-27.78M	-27.51M	-27.42M	-14.40M	-8.47M
Net Income	-27.43M	-30.44M	-30.01M	-28.52M	-14.65M	-8.56M
Balance Sheet
Total Assets	19.87M	20.94M	33.71M	33.04M	42.22M	20.91M
Cash, Cash Equivalents and Short-Term Investments	11.89M	11.12M	21.28M	18.18M	37.02M	17.99M
Total Debt	4.27M	5.03M	4.89M	5.87M	2.41M	174.00K
Total Liabilities	5.99M	6.47M	8.77M	10.31M	4.04M	2.59M
Stockholders Equity	13.88M	14.48M	24.94M	22.73M	38.18M	18.32M
Cash Flow
Free Cash Flow	-19.39M	-24.25M	-23.94M	-27.83M	-13.82M	-7.13M
Operating Cash Flow	-19.35M	-24.15M	-23.34M	-24.12M	-13.51M	-7.13M
Investing Cash Flow	-33.00K	-187.00K	-600.00K	-3.71M	-309.00K	0.00
Financing Cash Flow	18.35M	14.18M	27.04M	8.99M	32.95M	24.52M

IN8bio Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INAB, the sentiment is Neutral. The current price of 2.25 is above the 20-day moving average (MA) of 2.25, below the 50-day MA of 2.39, and below the 200-day MA of 6.13, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 49.20 is Neutral, neither overbought nor oversold. The STOCH value of 72.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for INAB.

IN8bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BOLT	52 Neutral	$10.54M	―	-83.92%	―	-67.87%	0.40%
Sector *	51 Neutral	$7.42B	-0.36	-44.95%	2.27%	22.89%	-2.16%
SABS	51 Neutral	$22.49M	―	-127.48%	―	-95.87%	35.25%
PHIO	42 Neutral	$10.27M	―	-76.12%	―	―	79.86%
IMNN	41 Neutral	$17.25M	―	-491.97%	―	―	45.96%
MEIP	41 Neutral	$31.92M	―	-89.73%	―	-100.00%	-221.06%
INAB	34 Underperform	$10.21M	―	-165.56%	―	―	58.67%